23 week, as banks rallied ahead of the central bank's policy review, while Sun Pharmaceutical Industries and Ranbaxy Laboratories surged ahead of a planned merger.
MUMBAI, April 1 (Reuters) - Indian shares rose on Wednesday, on track to snap a three-week losing streak, led by gains in pharmaceutical stocks such as Sun Pharmaceutical Industries and Ranbaxy Laboratories ahead of the latter's amalgamation with the former.
* To boost annual R&D spending to about $300 mln (Adds managing director comments)
MUMBAI, March 25 (Reuters) - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said on Wednesday its $3.2 billion acquisition of smaller rival Ranbaxy Laboratories Ltd will not restrict it from making further large acquisitions.
Sun Pharmaceuticals Industries and Ranbaxy , came through earlier this week ..... positive on the merger, as we believe Ranbaxy 's OTC and specialty drugs portfolio ..... are also present in the acquired Ranbaxy business. We believe the stock is
Quarterly revenue for the yet-to-merge Ranbaxy business was up 16% and profit turned ..... prior period and accounted for 44% of Ranbaxy 's quarterly sales). We believe ..... further enhanced with the addition of Ranbaxy to its portfolio.
largely the result of incorporating Ranbaxy financials into our forecast starting 1 April 2014. We believe the Ranbaxy acquisition will strengthen Sun ..... to expand the operating margins of Ranbaxy post-merger. These include manufacturing
fair value estimate for Sun Pharmaceuticals as we update our model for recent performance and integrate the acquisition of Ranbaxy into our forecast. We also are maintaining our narrow moat rating for the company. Sun continues to post strong growth
April bought Ranbaxy Laboratories for $4 billion from Japan’s Daiichi Sankyo . And French pharmaceutical ..... purchase of Ranbaxy Laboratories , the latter ..... Japan’s Daiichi Sankyo in 2008 bought a 64% stake in Ranbaxy for $4.2
but we remain concerned about possible margin pressure from internal regulatory issues and the upcoming integration of Ranbaxy . Sun's U.S. business continued to lead the charge with 43% growth, as currency benefits and pricing power in many